Evidence map›Paper›PMID 36493657›Full record

ArticleSleep medicine2023

Insomnia symptoms predict longer COVID-19 symptom duration.

Ivan Vargas, Alexandria Muench, Michael A Grandner, Michael R Irwin, Michael L Perlis

Open access · greenAbstract read
In one paragraph

Article in Sleep medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Prevalence and associations of insomnia after COVID-19 infection.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Ivan VargasDepartment of Psychological Science, University of Arkansas, Fayetteville, AR, USA. Electronic address: ivvargas@uark.edu.
Alexandria MuenchDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
Michael A GrandnerDepartment of Psychiatry, University of Arizona, USA.
Michael R IrwinCousins Center for Psychoneuroimmology, UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA, USA.
Michael L PerlisDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
University of Pennsylvania · USNeurobehavioral Systems · USUniversity of Arizona · USUniversity of Arkansas at Fayetteville · US

Funding

TRAINING PROGRAM/RESPIRATORY NEUROBIOLOGY AND SLEEPT32HL007713 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI PACK, ALLAN I · 1992 to 2022
$11.9M
Sleep and Cardiometabolic Health Disparities at the US/Mexico Border: The Nogales Cardiometabolic Health and Sleep (NoCHeS) StudyR01MD011600 · NIMHD · UNIVERSITY OF ARIZONA · PI GRANDNER, MICHAEL A · 2018 to 2022
$4.1M
Behavioral Sleep Medicine: Training in Sleep and AgingK24AG055602 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Michael Lloyd Perlis · 2017 to 2026
$1.6M
Circadian and Ultradian Cortisol Rhythms in Chronic Sleep Continuity DisturbanceK23HL141581 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI VARGAS, IVAN · 2019 to 2023
$677k
NHLBI NIH HHS K23 HL141581NHLBI NIH HHS T32 HL007713NIA NIH HHS K24 AG055602NIA NIH HHS L30 AG060532NIMHD NIH HHS R01 MD011600
6 · The paper itself

Abstract

objective/Background: The goal of the present study was to assess the prevalence and incidence of insomnia in the United States during the COVID-19 pandemic, and whether, among those that contracted COVID-19, insomnia predicted worse outcomes (e.g., symptoms of greater frequency, duration, or severity).

methodsA nationwide sample of 2980 adults living in the United States were surveyed online at two points during the COVID-19 pandemic (T1 = April-June 2020; T2 = January-March 2021). Insomnia symptoms were assessed at both time points using the Insomnia Severity Index (ISI). The T2 survey also asked questions regarding COVID-19 testing and symptoms.

resultsThe prevalence of insomnia (defined as ISI ≥15) was 15% at T1 and 13% at T2. The incidence rate of insomnia (i.e., new cases from T1 to T2) was 5.6%. Participants with insomnia were not more likely to contract COVID-19 relative to those participants without insomnia. Among those participants in our sample that contracted the virus during the study interval (n = 149), there were no significant group differences in COVID-19 symptom outcomes, with one exception, participants with insomnia were more likely to report a longer symptom duration (insomnia = 24.8 sick days, no insomnia = 16.1 sick days).

conclusionsThe present study suggests the prevalence of insomnia in the U.S. population remained high during the COVID-19 pandemic. The data also support that insomnia may be related to experiencing more chronic COVID-19 symptoms. These findings have more general implications for the role of sleep and insomnia on immune functioning.

Indexed as

COVID-19Sleep Initiation and Maintenance DisordersAdultCOVID-19 TestingHumansPandemicsSARS-CoV-2United StatesCOVID-19InsomniaPrevalenceSymptoms

Identifiers

PMID36493657
PMCPMC9682867
OpenAlexW4310010231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.